Milestone Pharmaceuticals INC Form 4 insider transactions

CEO Joseph Oliveto sold 36,500 shares of Milestone Pharmaceuticals under a pre-arranged Rule 10b5-1 trading plan.

Milestone Pharmaceuticals' President and CEO, Joseph Oliveto, filed an amended Form 4 to correct the exercise price of his employee stock options to $1.96.

Milestone Pharmaceuticals Inc. filed an amended Form 4 to correct the exercise price of Chief Medical Officer David Bharucha's employee stock options.

Milestone Pharmaceuticals' Chief Operating Officer, Jeffrey Edward Nelson, filed an amended Form 4 to correct the exercise price of 204,000 employee stock options.

Milestone Pharmaceuticals Inc. filed an amended Form 4 to correct the exercise price of Chief Commercial Officer Lorenz Muller's employee stock option to $1.96.

Milestone Pharmaceuticals Inc. filed an amended Form 4 to correct the exercise price of CFO Amit Hasija's employee stock options to $1.96.

Milestone Pharmaceuticals' Chief Commercial Officer, Lorenz Muller, received significant equity awards, including stock options and restricted stock units, effective February 2, 2026.

Milestone Pharmaceuticals Inc.'s CFO and EVP of Corporate Development, Amit Hasija, was granted 204,000 employee stock options and 136,000 restricted stock units.

Milestone Pharmaceuticals' Chief Operating Officer, Jeffrey Edward Nelson, was granted 204,000 stock options and 136,000 restricted stock units, effective February 2, 2026.

Milestone Pharmaceuticals' Chief Medical Officer, David Bharucha, was granted 340,000 equity awards, comprising stock options and restricted stock units.

Milestone Pharmaceuticals Inc. President and CEO Joseph Oliveto was granted 679,000 stock options and 453,000 restricted stock units, aligning his incentives with long-term shareholder value.

Milestone Pharmaceuticals' Chief Medical Officer, David Bharucha, reported the vesting of performance and restricted stock units, along with subsequent share sales to cover tax obligations, and the grant of new stock options.

Milestone Pharmaceuticals' Chief Operating Officer, Jeffrey Edward Nelson, reported recent acquisitions and sales of company common shares tied to equity award vestings and tax obligations.

Milestone Pharmaceuticals' Chief Commercial Officer, Lorenz Muller, reported recent acquisitions of common shares through PSU and RSU vesting, along with sales to cover tax liabilities, and a new stock option grant.

Milestone Pharmaceuticals' CFO, Amit Hasija, reported recent stock option grants, RSU and PSU vestings, and subsequent share sales to cover tax liabilities.

Milestone Pharmaceuticals Inc.'s President and CEO, Joseph Oliveto, reported the vesting of performance and restricted stock units, alongside related sell-to-cover transactions for tax liabilities.

Milestone Pharmaceuticals Inc.'s President and CEO, Joseph Oliveto, sold 43,500 common shares in early January 2026 under a pre-arranged Rule 10b5-1 trading plan.

Milestone Pharmaceuticals' Chief Commercial Officer, Lorenz Muller, reported gifting 25,000 common shares to family members.

Milestone Pharmaceuticals Inc. Director Debra K. Liebert has acquired 16,793 Issuer Units, including common shares and warrants, indicating a significant insider investment in the company.

Milestone Pharmaceuticals Inc.'s CFO and EVP of Corporate Development, Amit Hasija, has acquired 50,000 common shares and associated warrants, indicating strong management confidence in the company's future.

Milestone Pharmaceuticals Inc. Director Robert James Wills has acquired 50,000 common shares and 100,000 warrants through a unit purchase, increasing his beneficial ownership in the company.

Milestone Pharmaceuticals Inc.'s Chief Medical Officer, David Bharucha, acquired 53,333 common shares and an equal number of Series A and Series B warrants through a unit purchase, signaling strong insider confidence.

Milestone Pharmaceuticals Inc.'s President and CEO, Joseph Oliveto, has increased his direct beneficial ownership by acquiring 66,666 common shares and associated warrants through a unit purchase.

Milestone Pharmaceuticals Inc.'s Chief Commercial Officer, Lorenz Muller, has acquired 66,666 units, each comprising one common share and two types of warrants, signaling strong insider confidence.

Milestone Pharmaceuticals Inc. Director Joseph C. Papa has acquired 100,000 Issuer Units, comprising common shares and warrants, in a transaction dated July 11, 2025.

Milestone Pharmaceuticals Inc. Director Seth H. Z. Fischer was granted 40,000 stock options with an exercise price of $1.75, vesting over 12 months or by the next annual meeting.

Milestone Pharmaceuticals Inc. Director Joseph C. Papa was granted 40,000 stock options with an exercise price of $1.75, vesting over 12 months or by the next annual meeting.

Milestone Pharmaceuticals Inc. Director Michael John Tomsicek was granted 40,000 stock options with an exercise price of $1.75, vesting over 12 months.

Milestone Pharmaceuticals Inc. Director Robert James Wills was granted 40,000 stock options with an exercise price of $1.75, vesting over 12 months starting July 10, 2025.

Milestone Pharmaceuticals Inc. Director Stuart Duty has been granted 40,000 stock options with an exercise price of $1.75, vesting over 12 months.